COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®
COVID-19 Vaccine CoronaVac®Hub
Conditioned market authorization in China on February 5, 2021
The results of pre-clinical and clinical research trials were published in Science and Lancet Infect Diseases.
The Phase Ⅲ Clinical Trial and real-world studies showed that vaccination with CoronaVac® has a significant impact on reducing the incidence, hospitalization and death rate caused by COVID-19 infection.
Over 400 studies conducted worldwide showed its safety and efficacy among people aged 6 months old and above, including some special populations
Real-world studies showed it had effective protection against VOCs
The annual production capacity is over 2 billion doses
CoronaVac® vaccine has been approved for administration to adults in 62 countries, regions, and international organizations, and for children and adolescents in 14 countries and regions. CoronaVac® is the only inactivated COVID-19 vaccine currently approved for use in children as young as 6 months old
Nearly 290 million doses of vaccines have been delivered worldwide and recognized internationally and which can facilitate multi-national trade
